Clinical Trials Results - National Cancer Institute

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

In English \| En español
Search

NCI Home

Cancer Topics


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 135 for your search:

Drug:  imatinib mesylate
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571AUS177, US177, RIGHT Trial, NCT00081926

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BJP07, NCT00171977

Study Comparing Standard Dose and High-Dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571ACA09, NCT00171899

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571H2201, NCT00290771

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571H2202, NCT00292149

Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-043, EUDRACT Number: 2005-005153-22, NCT00320190

Phase III Randomized Study of STI571 vs Interferon Alfa and Cytarabine in Patients With Newly Diagnosed, Previously Untreated, Philadelphia Chromosome Positive, Chronic Phase Chronic Myelogenous Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NOVARTIS-CSTI5710106, FHCRC-1556.00, NCT00006343

Phase III Randomized Study of Two Different Doses of Imatinib Mesylate in Patients With CD117-Expressing Metastatic or Unresectable Gastrointestinal Stromal Tumor

Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 and over
Sponsor: NCI
Protocol IDs: CLB-80004, CAN-NCIC-S0033, E-S0033, SWOG-S0033, INT-S0033, NCT00009906, S0033

A Phase III Randomized Double-Blind Study of Adjuvant Imatinib Mesylate (Gleevec; STI571) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ACOSOG-Z9001, CAN-NCIC-SRC1, CALGB-ACOSOG-Z9001, SWOG-ACOSOG-Z9001, NCT00041197, UWCC-UW-6303, UWCC-UW-03-8438-A-03, SRC1

10.

Phase III Randomized Study of Allogeneic or Autologous Stem Cell Transplantation Versus Conventional Consolidation and Maintenance Chemotherapy in Patients With Acute Lymphoblastic Leukemia in First Remission

Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: NCI
Protocol IDs: ECOG-2993, MRC-LEUK-UKALL-XII, EST-4491, INT-0132, NCT00002514

11.

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SSGXVIII/AIO, NCT00116935

12.

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571K2301, NCT00124748

13.

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE40, NCT00154375

14.

Open-Label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CECOG/GIST 1.2.001, CSTI571BIC07, NCT00293124

15.

Phase III Randomized Study of Imatinib Mesylate in Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0511009-01, NOVARTIS-CSTI571K2301, EUDRACT-2005-00657-29, FWA00004642, NCT00324636

16.

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2303, NCT00471497

17.

A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-056, NCT00481247

18.

A Study of Imatinib Versus Nilotinib in Adult Patients With a Suboptimal Cytogenetic Response With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2302, NCT00519090

19.

Phase III Randomized Study of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor That Expresses KIT (CD117)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62005, AGITG-AGO102-GIST, EORTC 62005, ISG-62005, SSG-15, NCT00685828

20.

Phase I/II Study of STI571 in Patients With Recurrent or Refractory Soft Tissue Sarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 15 and over
Sponsor:
Protocol IDs: EORTC-62001, EORTC-16003, NOVARTIS-CSTI5710203, NCT00006357

21.

Phase I/II Study of Imatinib Mesylate in Patients With Recurrent Malignant Glioma or Meningioma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTC-9908, NCI-01-C-0243, UCLA-0101024, NCT00010049

22.

Phase I/II Study of Imatinib Mesylate and High-Dose Cytarabine in Patients With Blastic Phase Chronic Myelogenous Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCLA-0011009, UCLA-NCI-1870, NCI-1870, NCT00015834, 1870

23.

Phase I/II Study of Imatinib Mesylate Combined With Daunorubicin, Vincristine, and Prednisone in Patients With Lymphoid Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCLA-0011010, UCLA-NCI-4292, NCI-4292, NCT00015860, 4292

24.

Phase I/II Study of Imatinib Mesylate With or Without Radiotherapy in Children With Newly Diagnosed Poor Prognosis Brainstem Glioma or Recurrent High-Grade Intracranial Glioma (Phase I, strata I and IIA closed to accrual as of 5/10/04.)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: PBTC-006, NCT00021229

25.

Phase I/II Study of Imatinib Mesylate and Cytarabine in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2001-03, HOVON-51CML, EU-20132, HOVON-CKTO-2001-03, NOVARTIS-CST1571ANL01, NCT00028847

Select All on Page

Help with Results

A Service of the National Cancer Institute